LOGIN  |  REGISTER
Chimerix

BrightSpring Health Services to Participate in Three Upcoming Investor Conferences

May 22, 2024 | Last Trade: US$15.09 0.22 1.48

LOUISVILLE, Ky., May 22, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that Company management will participate at three upcoming investor conferences.

  • 2024 Leerink Partners Healthcare Crossroads Conference
    Fireside Chat on Thursday, May 30th at 8:40am CT
  • Jefferies Global Healthcare Conference
    Fireside Chat on Thursday, June 6th at 9am ET
  • Goldman Sachs 45th Annual Global Healthcare Conference
    Fireside Chat on Monday, June 10th at 11:20am ET

Live and archived webcasts of the events will be available on the “Event & Presentations” section of the BrightSpring investor relations website at https://ir.brightspringhealth.com/.

About BrightSpring Health Services

BrightSpring Health Services is the parent company of leading service lines that provide integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the company’s service lines, including pharmacy, primary care and home health care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily. For more information, visit www.brightspringhealth.com.

Contact

Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact:
Leigh White
This email address is being protected from spambots. You need JavaScript enabled to view it. 
502.630.7412

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB